1.McFarland, LV, Mulligan, ME, Kwok, RY, et al.Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204–210.
2.Shanholtzer, CJ, Willard, KE, Holter, JJ, et al.Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests. J Clin Microbiol 1992;30:1837–1840.
3.Shim, JK, Johnson, S, Samore, MH, et al.Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998;351:633–636.
4.Walker, RC, Ruane, PJ, Rosenblatt, JE, et al.Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. Diagn Microbiol Infect Dis 1986;5:61–69.
5.Kyne, L, Warny, M, Qamar, A, et al.Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390–397.
6.Louie, TJ, Peppe, J, Watt, CK, et al.Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:411–420.
7.Musher, DM, Logan, N, Hamill, RJ, et al.Nitazoxanide for the treatment of Clostridium diffidle colitis. Clin Infect Dis 2006;43:421–427.
8.Kuijper, EJ, Coignard, B, Tuli, P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(Suppl 6):2–18.
9.Gerding, DN, Olson, MM, Peterson, LR, et al.Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986;146:95–100.
10.Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.
11.Kyne, L, Merry, C, O'Connell, B, et al.Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 1999;28:107–113.
12.Bartlett, JG. Antibiotic-associated colitis. Dis Mon 1984;30:1–54.
13.Bartlett, JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334–349.
14.Kelly, CP, Pothoulakis, C, LaMont, JT. Clostridium diffidle colitis. N Engl J Med 1994;330:257–262.
15.Hall, IC, O'Toole, E. Intestinal flora in new-born infants. Am J Dis Child 1935;49:390–402.
16.Viscidi, R, Willey, S, Bartlett, JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981;81:5–9.
17.Aronsson, B, Mollby, R, Nord, CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J Infect Dis 1985;151:476–481.
18.Nakamura, S, Mikawa, M, Nakashio, S, et al.Isolation of Clostridium diffidle from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol 1981;25:345–351.
19.Burdon, DW. Clostridium difficile, the epidemiology and prevention of hospital-acquired infection. Infection 1982;10:203–204.
20.Larson, HE, Barclay, FE, Honour, P, et al.Epidemiology of Clostridium diffidle in infants. J Infect Dis 1982;146:727–733.
21.Larson, HE, Price, AB, Bordello, SP. Epidemiology of experimental en-terocecitis due to Clostridium difficile. J Infect Dis 1980;142:408–413.
22.Toshniwal, R, Silva, J Jr, Fekety, R, et al.Studies on the epidemiology of colitis due to Clostridium difficile in hamsters. J Infect Dis 1981;143:51–54.
23.Johnson, S, Clabots, CR, Linn, FV, et al.Nosocomial Clostridium difficile colonisation and disease. Lancet 1990;336:97–100.
24.McDonald, LC, Killgore, GE, Thompson, A, et al.An epidemic, toxin gene-variant strain of Clostridium difficile. NEngl J Med 2005;353:2433–2441.
25.Loo, VG, Poirier, L, Miller, MA, et al.A predominantly clonal multi-institutional outbreak of Clostridium diffidle-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.
26.Voth, DE, Ballard, JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005;18:247–263.
27.Samore, MH, DeGirolami, PC, Tlucko, A, et al.Clostridium diffidle colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994;18:181–187.
28.Olson, MM, Shanholtzer, CJ, Lee, JT Jr, et al.Ten years of prospective Clostridium diffidle-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994;15:371–381.
29.Triadafilopoulos, G, Hailstone, AE. Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology 1991;101:685–691.
30.Wolf, LE, Gorbach, SL, Granowitz, EV. Extraintestinal Clostridium difficile: 10 years' experience at a tertiary-care hospital. Mayo Clin Proc 1998;73:943–947.
31.Pron, B, Merckx, J, Touzet, P, et al.Chronic septic arthritis and osteomyelitis in a prosthetic knee joint due to Clostridium difficile. Eur J Clin Microbiol Infect Dis 1995;14:599–601.
32.Studemeister, AE, Beilke, MA, Kirmani, N. Splenic abscess due to Clostridium difficile and Pseudomonas paucimobilis. Am J Gastroenterol 1987;82:389–390.
33.Feldman, RJ, Kallich, M, Weinstein, MP. Bacteremia due to Clostridium difficile: case report and review of extraintestinal C. difficile infections. Clin Infect Dis 1995;20:1560–1562.
34.Freiler, JF, Durning, SJ, Ender, PT. Clostridium diffidle small bowel enteritis occurring after total colectomy. Clin Infect Dis 2001;33:1429–1431.
35.Wanahita, A, Goldsmith, EA, Marino, BJ, et al.Clostridium diffidle infection in patients with unexplained leukocytosis. Am J Med 2003;115:543–546.
36.Wanahita, A, Goldsmith, EA, Musher, DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002;34:1585–1592.
37.Gerding, DN, Johnson, S, Peterson, LR, et al.Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459–477.
38.Field, MJ, Lohr, KN. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, Clinical Practice Guidelines: Directions for a New Program. Washington, DC: Institute of Medicine; 1990.
39.The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979;121:1193–1254.
40.Miller, MA, Hyland, M, Ofher-Agostini, M, et al.Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137–140.
41.Miller, MA, Gravel, D, Mulvey, M, et al.Surveillance for nosocomial Clostridium difficile associated diarrhea (N-CDAD) within acute-care hospitals in Canada: results of the 2005 nosocomial infections surveillance program (CNISP) study shows escalating mortality. In: Proceedings of the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18-21, 2006; Chicago, IL.
42.Walker, KJ, Gilliland, SS, Vance-Bryan, K, et al.Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc 1993;41:940–946.
43.Simor, AE, Bradley, SF, Strausbaugh, LJ, et al.Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002;23:696–703.
44.Kyne, L, Hamel, MB, Polavaram, R, et al.Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346–353.
45.O'Brien, JA, Lahue, BJ, Caro, JJ, et al.The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:1219–1227.
46.McDonald, LC, Owings, M, Jernigan, DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409–415.
47.Pepin, J, Alary, ME, Valiquette, L, et al.Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591–1597.
48.Muto, CA, Pokrywka, M, Shutt, K, et al.A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273–280.
50.Eggertson, L. Quebec strain of C. difficile in 7 provinces. Can Med Assoc 2006;174:607–608.
51.Warny, M, Pepin, J, Fang, A, et al.Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079–1084.
52.Health Protection Agency. Outbreak of Clostridium difficile infection in a hospital in southeast England. CDR Weekly 2005;15(24).
53.Kuijper, EJ, Debast, SB, Van Kregten, E, et al.Clostridium difficile ribo-type 027, toxinotype III in The Netherlands [in Dutch]. Ned Tijdschr Geneeskd 2005;149:2087–2089.
54.Kuijper, EJ, Barbut, F, Brazier, JS, et al.Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008;13(31):pii:18942.
55.Kato, H, Ito, Y, van den Berg, RJ, et al.First isolation of Clostridium difficile 027 in Japan. Euro Surveill 2007;12:E0701113.
56.Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:1201–1205.
57.James, AH, Katz, VL, Dotters, DJ, et al.Clostridium difficile infection in obstetric and gynecologic patients. South Med J 1997;90:889–892.
58.Kyne, L, Merry, C, O'Connell, B, et al.Community-acquired Clostridium diffidle infection. J Infect 1998;36:287–288.
59.Johal, SS, Hammond, J, Solomon, K, et al.Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004;53:673–677.
60.Terhes, G, Urban, E, Sold, J, et al.Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol 2004;42:4316–4318.
61.Dial, S, Delaney, JA, Barkun, AN, et al.Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium diffidle-associated disease. JAMA 2005;294:2989–2995.
62.Hirschhorn, LR, Trnka, Y, Onderdonk, A, et al.Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994;169:127–133.
63.Levy, DG, Stergachis, A, McFarland, LV, et al.Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther 2000;22:91–102.
64.Frost, F, Hurley, JS, Petersen, HV, et al.Estimated incidence of Clostridium difficile infection. Emerg Infect Dis 1999;5:303–304.
65.Rivera, EV, Woods, S. Prevalence of asymptomatic Clostridium difficile colonization in a nursing home population: a cross-sectional study. J Gend Specif Med 2003;6:27–30.
66.Fekety, R, Kim, KH, Brown, D, et al.Epidemiology of antibiotic-associated colitis: isolation of Clostridium difficile from the hospital environment. Am J Med 1981;70:906–908.
67.Riggs, MM, Sethi, AK, Zabarsky, TF, et al.Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007;45:992–998.
68.McFarland, LV, Surawicz, CM, Greenberg, RN, et al.Possible role of cross-transmission between neonates and mothers with recurrent Clostridium difficile infections. Am J Infect Control 1999;27:301–303.
69.Kyne, L, Warny, M, Qamar, A, et al.Association between antibody response to toxin A and protection against recurrent Clostridium diffidle diarrhoea. Lancet 2001;357:189–193.
70.Sambol, SP, Tang, JK, Merrigan, MM, et al.Infection of hamsters with epidemiologically important strains of Clostridium difficile. J Infect Dis 2001;183:1760–1766.
71.Anand, A, Bashey, B, Mir, T, et al.Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994;89:519–523.
72.Palmore, TN, Sohn, S, Malak, SF, et al.Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 2005;26:680–684.
73.Chang, H, Parada, J, Evans, C, et al.Onset of symptoms and time to diagnosis of Clostridium difficile diarrhea among outpatients discharged from an acute care hospital [abstract]. In: Proceedings of The 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18-21, 2006; Chicago, IL: 108–109.
74.Mayfield, J, McMullen, K, Dubberke, E. Comparison of Clostridium diffidle-associated disease rates using a traditional vs. expanded definition. In: Proceedings of The 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18-21, 2006; Chicago, IL: 115.
75.Samore, MH, Venkataraman, L, DeGirolami, PC, et al.Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996;100:32–40.
76.Mayfield, JL, Leet, T, Miller, J, et al.Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000;31:995–1000.
77.Fawley, WN, Wilcox, MH. Molecular epidemiology of endemic Clostridium diffidle infection. Epidemiol Infect 2001;126:343–350.
78.Wilcox, MH, Fawley, WN, Wigglesworth, N, et al.Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 2003;54:109–114.
79.Brooks, SE, Veal, RO, Kramer, M, et al.Reduction in the incidence of Clostridium diffidle-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Infect Control Hosp Epidemiol 1992;13:98–103.
80.Pepin, J, Valiquette, L, Alary, ME, et al.Clostridium diffidle-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466–472.
81.Johnson, S, Samore, MH, Farrow, KA, et al.Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341:1645–1651.
82.Privitera, G, Scarpellini, P, Ortisi, G, et al.Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 1991;35:208–210.
83.Yee, J, Dixon, CM, McLean, AP, et al.Clostridium difficile disease in a department of surgery: the significance of prophylactic antibiotics. Arch Surg 1991;126:241–246.
84.Anand, A, Glatt, AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993;17:109–113.
85.Morales Chamorro, R, Serrano Blanch, R, Mendez Vidal, MJ, et al.Pseudomembranous colitis associated with chemotherapy with 5-fluoro-uracil. Clin Transi Oncol 2005;7:258–261.
86.Bilgrami, S, Feingold, JM, Dorsky, D, et al.Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;23:1039–1042.
87.Gorschluter, M, Glasmacher, A, Hahn, C, et al.Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001;33:786–791.
88.Sanchez, TH, Brooks, JT, Sullivan, PS, et al.Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis 2005;41:1621–1627.
89.Thibault, A, Miller, MA, Gaese, C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol 1991;12:345–348.
90.Bliss, DZ, Johnson, S, Savik, K, et al.Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998;129:1012–1019.
91.Cunningham, R, Dale, B, Undy, B, et al.Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243–245.
92.Dial, S, Alrasadi, K, Manoukian, C, et al.Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33–38.
93.Al-Jumaili, IJ, Shibley, M, Lishman, AH, et al.Incidence and origin of Clostridium difficile in neonates. J Clin Microbiol 1984;19:77–78.
94.Shah, S, Lewis, A, Leopold, D, et al.Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000;93:175–181.
95.McDonald, LC, Coignard, B, Dubberke, E, et al.Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007;28:140–145.
96.Cohen, SH, Tang, YJ, Silva, J Jr. Molecular typing methods for the epidemiological identification of Clostridium difficile strains. Expert Rev Moi Diagn 2001;1:61–70.
97.Tang, YJ, Houston, ST, Gumerlock, PH, et al.Comparison of arbitrarily primed PCR with restriction endonuclease and immunoblot analyses for typing Clostridium difficile isolates. J Clin Microbiol 1995;33:3169–3173.
98.Gal, M, Northey, G, Brazier, JS. A modified pulsed-field gel electrophoresis (PFGE) protocol for subtyping previously non—PFGE typeable isolates of Clostridium diffidle polymerase chain reaction ribotype 001. J Hosp Infect 2005;61:231–236.
99.Rupnik, M, Avesani, V, Jane, M, et al.A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998;36:2240–2247.
100.Wullt, M, Burman, LG, Laureil, MH, et al.Comparison of AP-PCR typing and PCR-ribotyping for estimation of nosocomial transmission of Clostridium difficile. J Hosp Infect 2003;55:124–130.
101.Northey, G, Gal, M, Rahmati, A, et al.Subtyping of Clostridium difficile PCR ribotype 001 by REP-PCR and PFGE. J Med Microbiol 2005;54:543–547.
102.Stubbs, SL, Brazier, JS, O'Neill, GL, et al.PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium diffidle and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999;37:461–463.
103.Lemee, L, Bourgeois, I, Ruffin, E, et al.Multilocus sequence analysis and comparative evolution of virulence-associated genes and housekeeping genes of Clostridium difficile. Microbiology 2005;151:3171–3180.
104.Marsh, JW, O'Leary, MM, Shutt, KA, et al.Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in hospitals. J Clin Microbiol 2006;44:2558–2566.
105.van den Berg, RJ, Schaap, I, Templeton, KE, et al.Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis. J Clin Microbiol 2007;45:1024–1028.
106.Killgore, G, Thompson, A, Johnson, S, et al.Comparison of seven techniques for typing international epidemic strains of Clostridium difficile. restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 2008;46:431–437.
107.Lyras, D, O'Connor, JR, Howarth, PM, et al.Toxin B is essential for virulence of Clostridium diffidle. Nature 2009;458:1176–1179.
108.Alfa, MJ, Swan, B, VanDekerkhove, B, et al.The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. diffidle panel, EIA for Tox A/B and cytotoxin assays. Diagn Microbiol Infect Dis 2002;43:257–263.
109.Fedorko, DP, Engler, HD, O'Shaughnessy, EM, et al.Evaluation of two rapid assays for detection of Clostridium difficile toxin A in stool specimens. J Clin Microbiol 1999;37:3044–3047.
110.Ticehurst, JR, Aird, DZ, Dam, LM, et al.Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006;44:1145–1149.
111.Planche, T, Aghaizu, A, Holliman, R, et al.Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008;8:777–784.
113.Bouza, E, Munoz, P, Alonso, R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 2005;11(Suppl 4):57–64.
114.Kuijper, EJ, van den Berg, RJ, Debast, S, et al.Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis 2006;12:827–830.
115.Reller, ME, Lema, CA, Perl, TM, et al.Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol 2007;45:3601–3605.
116.Gerding, DN. Diagnosis of Clostridium difficile-associated disease: patient selection and test perfection. Am J Med 1996;100:485–486.
117.Katz, DA, Lynch, ME, Littenberg, B. Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med 1996;100:487–495.
118.Aichinger, E, Schleck, CD, Harmsen, WS, et al.Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008;46:3795–3797.
119.Larson, HE, Parry, JV, Price, AB, et al.Undescribed toxin in pseudomembranous colitis. Br Med J 1977;1:1246–1248.
120.Barbut, F, Lalande, V, Burghoffer, B, et al.Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Miaobiol 2002;40:2079–2083.
121.Tichota-Lee, J, Jaqua-Stewart, MJ, Benfield, D, et al.Effect of age on the sensitivity of cell cultures to Clostridium difficile toxin. Diagn Microbiol Infect Dis 1987;8:203–214.
122.Peterson, LR, Olson, MM, Shanholtzer, CJ, et al.Results of a prospective, 18-month clinical evaluation of culture, cytotoxin testing, and culturette brand (CDT) latex testing in the diagnosis of Clostridium difficile-associated diarrhea. Diagn Microbiol Infect Dis 1988;10:85–91.
123.Johnson, S, Kent, SA, O'Leary, KJ, et al.Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med 2001;135:434–438.
124.George, WL, Sutter, VL, Citron, D, et al.Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 1979;9:214–219.
125.Wilcox, MH, Fawley, WN, Parnell, P. Value of lysozyme agar incorporation and alkaline thioglycollate exposure for the environmental recovery of Clostridium diffidle. J Hosp Infect 2000;44:65–69.
126.Snell, H, Ramos, M, Longo, S, et al.Performance of the Tech Lab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 2004;42:4863–4865.
127.Zheng, L, Keller, SF, Lyerly, DM, et al.Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol 2004;42:3837–3840.
128.Barbut, F, Lalande, V, Daprey, G, et al.Usefulness of simultaneous detection of toxin A and glutamate dehydrogenase for the diagnosis of Clostridium difficile-associated diseases. Eur J Clin Microbiol Infect Dis 2000;19:481–484.
129.Massey, V, Gregson, DB, Chagla, AH, et al.Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of Clostridium difficile diarrhea. Am J Clin Pathol 2003;119:45–49.
130.Sloan, LM, Duresko, BJ, Gustafson, DR, et al.Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium diffidle infection, J Clin Microbiol 2008;46:1996–2001.
131.Vonberg, RP, Kuijper, EJ, Wilcox, MH, et al.Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008;14(Suppl 5):2–20.
132.Clabots, CR, Johnson, S, Olson, MM, et al.Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166:561–567.
133.Zafar, AB, Gaydos, LA, Furlong, WB, et al.Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Am J Infect Control 1998;26:588–593.
134.Apisarnthanarak, A, Zack, JE, Mayfield, JL, et al.Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile. Clin Infect Dis 2004;39:601–602.
135.Stone, SP, Berk, V, Quick, A, et al.The effect of an enhanced infection-control policy on the incidence of Clostridium difficile infection and methicillin-resistant Staphyloccocus aureus colonization in acute elderly medical patients. Age Ageing 1998;27:561–568.
136.Cartmill, TD, Panigrahi, H, Worsley, MA, et al.Management and control of a large outbreak of diarrhoea due to Clostridium difficile, J Hosp Infect 1994;27:1–15.
137.Boyce, JM, Pittet, D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002;51:1–45.
138.Pittet, D, Mourouga, P, Perneger, TV. Compliance with handwashing in a teaching hospital. Infection Control Program. Ann Intern Med 1999;130:126–130.
139.Boyce, JM. Using alcohol for hand antisepsis: dispelling old myths. Infect Control Hosp Epidemiol 2000;21:438–441.
140.Teare, L, Cookson, B, Stone, S. Hand hygiene. BMJ 2001;323:411–412.
141.Wullt, M, Odenholt, I, Walder, M. Activity of three disinfectants and acidified nitrite against Clostridium diffidle spores. Infect Control Hosp Epidemiol 2003;24:765–768.
142.Clabots, CR, Gerding, SJ, Olson, MM, et al.Detection of asymptomatic Clostridium difficile carriage by an alcohol shock procedure. J Clin Microbiol 1989;27:2386–2387.
143.Gordin, FM, Schultz, ME, Huber, RA, et al.Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. Infect Control Hosp Epidemiol 2005;26:650–653.
144.Oughton, M, Loo, V, Fenn, S, Lynch, A, Libman, M. Alcohol rub and antiseptic wipes are inferior to soap and water for removal of Clostridium difficile by handwashing. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, IL. Washington, DC: ASM Press; 2007.
145.Bettin, K, Clabots, C, Mathie, P, et al.Effectiveness of liquid soap vs. Chlorhexidine gluconate for the removal of Clostridium difficile from bare hands and gloved hands. Infect Control Hosp Epidemiol 1994;15:697–702.
146.Struelens, MJ, Maas, A, Nonhoff, C, et al.Control of nosocomial transmission of Clostridium difficile based on sporadic case surveillance. Am J Med 1991;91:138S–144S.
147.Cartmill, TD, Shrimpton, SB, Panigrahi, H, et al.Nosocomial diarrhoea due to a single strain of Clostridium difficile, a prolonged outbreak in elderly patients. Age Ageing 1992;21:245–249.
148.Lai, KK, Melvin, ZS, Menard, MJ, et al.Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control, infect Control Hosp Epidemiol 1997;18:628–632.
149.Garner, JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996;17:53–80.
150.Johnson, S, Gerding, DN, Olson, MM, et al.Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990;88:137–140.
151.Perry, C, Marshall, R, Jones, E. Bacterial contamination of uniforms. J Hosp Infect 2001;48:238–241.
152.Berild, D, Smaabrekke, L, Halvorsen, DS, et al.Clostridium difficile infections related to antibiotic use and infection control facilities in two university hospitals. J Hosp infect 2003;54:202–206.
153.Dettenkofer, M, Seegers, S, Antes, G, et al.Does the architecture of hospital facilities influence nosocomial infection rates? A systematic review. Infect Control Hosp Epidemiol 2004;25:21–25.
154.The American Institute of Architects Academy of Architecture for Health and the Facilities Guidelines Institute. Guidelines for design and construction of health care facilities. Washington, DC: American Institute of Architects Press, 2006.
155.Strimling, MO, Sacho, H, Berkowitz, I. Clostridium difficile infection in health-care workers. Lancet 1989;2:866–867.
156.Arfons, L, Ray, AJ, Donskey, CJ. Clostridium difficile infection among health care workers receiving antibiotic therapy. Clin Infect Dis 2005;40:1384–1385.
157.Cohen, RS, DiMarino, AJ Jr, Allen, ML. Fecal Clostridium difficile carriage among medical housestaff. N J Med 1994;91:327–330.
158.Brown, E, Talbot, GH, Axelrod, P, et al.Risk factors for Clostridium difficile toxin-associated diarrhea, infect Control Hosp Epidemiol 1990 11:283–290.
159.Delmee, M, Vandercam, B, Avesani, V, et al.Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. Eur J Clin Microbiol 1987;6:623–627.
160.Bender, BS, Bennett, R, Laughon, BE, et al.Is Clostridium difficile endemic in chronic-care facilities? Lancet 1986;2:11–13.
161.Johnson, S, Homann, SR, Bettin, KM, et al.Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann Intern Med 1992;117:297–302.
162.Hota, B. Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection? Clin Infect Dis 2004;39:1182–1189.
163.O'Neill, G, Adams, JE, Bowman, RA, et al.A molecular characterization of Clostridium diffidle isolates from humans, animals and their environments. Epidemiol Infect 1993;111:257–264.
164.Kim, KH, Fekety, R, Batts, DH, et al.Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981;143:42–50.
165.Fawley, WN, Underwood, S, Freeman, J, et al.Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. Infect Control Hosp Epidemiol 2007;28:920–925.
166.Manian, FA, Meyer, L, Jenne, J. Clostridium difficile contamination of blood pressure cuffs: a call for a closer look at gloving practices in the era of universal precautions. Infect Control Hosp Epidemiol 1996;17:180–182.
167.Brooks, S, Khan, A, Stoica, D, et al.Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers. Infect Control Hosp Epidemiol 1998;19:333–336.
168.Jernigan, JA, Siegman-Igra, Y, Guerrant, RC, et al.A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections. Infect Control Hosp Epidemiol 1998;19:494-49.
169.Kaatz, GW, Gitlin, SD, Schaberg, DR, et al.Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 1988;127:1289–1294.
170.Boyce, JM, Havill, NL, Otter, JA, et al.Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Infect Control Hosp Epidemiol 2008;29:723–729.
171.Rutala, WA, Gergen, MF, Weber, DJ. Inactivation of Clostridium difficile spores by disinfectants. Infect Control Hosp Epidemiol 1993;14:36–39.
172.Block, C. The effect of Perasafe and sodium dichloroisocyanurate (NaDCC) against spores of Clostridium diffidle and Badllus atrophaeus on stainless steel and polyvinyl chloride surfaces. J Hosp Infect 2004;57:144–148.
173.Perez, J, Springthorpe, VS, Sattar, SA. Activity of selected oxidizing microbicides against the spores of Clostridium diffidle-. relevance to environmental control. Am J Infect Control 2005;33:320–325.
174.Chang, HT, Krezolek, D, Johnson, S, et al.Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospital. Infect Control Hosp Epidemiol 2007;28:926–931.
175.McFarland, LV, Surawicz, CM, Stamm, WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990;162:678–684.
176.Wistrom, J, Norrby, SR, Myhre, EB, et al.Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001;47:43–50.
177.Bignardi, GE. Risk factors for Clostridium diffidle infection. J Hosp Infect 1998;40:1–15.
178.Davey, P, Brown, E, Fenelon, L, et al.Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005;19:CD003543.
179.Pear, SM, Williamson, TH, Bettin, KM, et al.Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120:272–277.
180.Climo, MW, Israel, DS, Wong, ES, et al.Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium diffidle-associzted diarrhea and cost. Ann Intern Med 1998;128:989–995.
181.Carling, P, Fung, T, Killion, A, et al.Favorable impact of a multidisci-plinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003;24:699–706.
182.McNulty, C, Logan, M, Donald, IP, et al.Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997;40:707–711.
183.Khan, R, Cheesbrough, J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infed 2003;54:104–108.
184.Wilcox, MH, Freeman, J, Fawley, W, et al.Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;54:168–172.
185.Alston, WK, Ahem, JW. Increase in the rate of nosocomial Clostridium diffidle-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin. J Antimicrob Chemother 2004;53:549–550.
186.Valiquette, L, Cossette, B, Garant, MP, et al.Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associzted disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007;45(Suppl 2):S112–S121.
187.Gaynes, R, Rimland, D, Killum, E, et al.Outbreak of Clostridium diffidle infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640–645.
188.Biller, P, Shank, B, Lind, L, et al.Moxifloxacin therapy as a risk factor for Clostridium difficile-associzted disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007;28:198–201.
189.Hickson, M, D'Souza, AL, Muthu, N, et al.Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335:80.
190.Teasley, DG, Gerding, DN, Olson, MM, et al.Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983;2:1043–1046.
191.Wenisch, C, Parschalk, B, Hasenhundl, M, et al.Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium diffidle-associated diarrhea. Clin Infect Dis 1996;22:813–818.
192.Wullt, M, Odenholt, I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium diffidle-associated diarrhoea. J Antimicrob Chemother 2004;54:211–216.
193.Bricker, E, Garg, R, Nelson, R, Loza, A, Novak, T, Hansen, J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2005(1):CD004610.
194.Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44(RR-12):1–13.
195.Fekety, R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:739–750.
196.Bolton, RP, Culshaw, MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986;27:1169–1172.
197.Keighley, MR, Burdon, DW, Arabi, Y, et al.Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. BMJ 1978;2:1667–1669.
198.Baird, DR. Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile. J Antimicrob Chemother 1989;23:167–169.
199.Olsson-Liljequist, B, Nord, CE. In vitro susceptibility of anaerobic bacteria to nitroimidazoles. Scand J Infect Dis Suppl 1981;26:42–45.
200.Wong, SS, Woo, PC, Luk, WK, et al.Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999;34:1–6.
201.Freeman, J, Stott, J, Baines, SD, et al.Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 2005;56:988–989.
202.Drummond, LJ, McCoubrey, J, Smith, DG, et al.Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric inpatients over an 18-month period. J Med Microbiol 2003;52:259–263.
203.Aspevall, O, Lundberg, A, Burman, LG, et al.Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 2006;50:1890–1892.
204.Pelaez, T, Alcala, L, Alonso, R, et al.In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005;49:1157–1159.
205.Baines, SD, O'Connor, R, Freeman, J, et al.Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008;62:1046–1052.
206.Musher, DM, Aslam, S, Logan, N, et al.Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586–1590.
207.Bishara, J, Bloch, Y, Garty, M, et al.Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis 2006;54:141–144.
208.Lamontagne, F, Labbe, AC, Haeck, O, et al.Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007;245:267–272.
209.Belmares, J, Gerding, DN, Parada, JP, et al.Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007;55:495–501.
210.Pepin, J, Valiquette, L, Gagnon, S, et al.Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP 1/027. Am J Gastroenterol 2007;102:2781–2788.
211.Zar, FA, Bakkanagari, SR, Moorthi, KM, et al.A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302–307.
212.Louie, T, Gerson, M, Grimard, D, et al.Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). In: Proceedings of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, IL. Washington, DC: ASM Press; 2007. Abstract K-425a
213.Apisarnthanarak, A, Razavi, B, Mundy, LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35:690–696.
214.McPherson, S, Rees, CJ, Ellis, R, et al.Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006;49:640–645.
215.Longo, WE, Mazuski, JE, Virgo, KS, et al.Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004;47:1620–1626.
216.Bartlett, JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984;6(Suppl 1):S235–S241.
217.Bartlett, JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992;15:573–581.
218.Barbut, F, Richard, A, Hamadi, K, et al.Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000;38:2386–2388.
219.Johnson, S, Adelmann, A, Clabots, CR, et al.Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989;159:340–33.
220.Pepin, J, Saheb, N, Coulombe, MA, et al.Emergence of fluoroquinolones as the predominant risk factor for Clostridium diffidle-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–1260.
221.Nair, S, Yadav, D, Corpuz, M, et al.Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation. Am J Gastroenterol 1998;93:1873–1876.
222.Pepin, J, Routhier, S, Gagnon, S, et al.Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758–764.
223.Kapoor, K, Chandra, M, Nag, D, et al.Evaluation of metronidazole toxicity: a prospective study. Int J Clin Pharmacol Res 1999;19:83–88.
224.Lagrotteria, D, Holmes, S, Smieja, M, et al.Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:547–552.
225.Johnson, S, Schriever, C, Galang, M, et al.Interruption of recurrent Clostridium diffidle-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846–848.
226.Curry, SR, Marsh, JW, Shutt, KA, et al.High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009;48:425–429.
227.Enache-Angoulvant, A, Hennequin, C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005;41:1559–1568.
228.Dendukuri, N, Costa, V, McGregor, M, et al.Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005;173:167–170.
229.Gustafsson, A, Lund-Tonnesen, S, Berstad, A, et al.Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol 1998;33:721–727.
230.Aas, J, Gessert, CE, Bakken, JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36:580–585.
231.Giannasca, PJ, Warny, M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 2004;22:848–856.
232.Wilcox, MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;53:882–884.
233.Salcedo, J, Keates, S, Pothoulakis, C, et al.Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997;41:366–370.